| Project/Area Number |
20591566
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | University of Yamanashi |
|---|
Principal Investigator |
KONO Koji University of Yamanashi, 大学院・医学工学総合研究部, 准教授 (40283204)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KAWAGUCHI Yoshihiko 山梨大学, 医学部附属病院, 診療助教 (80402048)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
NAKAMURA Yusuke 東京大学, 医科学研究所, 教授 (70217909)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2008: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | 癌ワクチン療法 / 食道癌 / ペプチド抗原 / Cancer-testis抗原 / 食道扁平上皮がん / 食道がん / ペプチドワクチン / 免疫療法 / 癌拒絶抗原 |
|---|
| Research Abstract |
We previously identified three novel HLA-A24-restricted epitope peptides, which were derived from three Cancer-Testis antigens, TTK, URLC10, and KOC1, as targets for cancer vaccination against esophageal squamous cell carcinoma (ESCC). To examine the safety, immunogenicity, and anti-tumor effect of vaccine treatment using a combination of these three peptides, ten HLA-A2402-positive advanced ESCC patients who failed to standard therapy were enrolled in a phase I clinical trial. The cancer vaccination therapy was well-tolerated without any treatment-associated adverse events of grade 3 or 4. The TTK-, LY6K-, and/or IMP-3-specific T-cell immune responses were observed by enzyme-linked immunospot assay in peripheral blood lymphocytes obtained from 9 of the 10 ESCC patients after their vaccination. The vaccination could induce good clinical responses in 50% of the 10 patients. One patient experienced a complete response in hepatic metastasis lasting 7 months, one showed objective responses in all lung metastasis lesions and three patients revealed a stable disease condition for at least 2.5 months. The cancer vaccine therapy using these three peptides demonstrated satisfactory safety and good immunogenicity as well as promising disease control rate, and, therefore, warrants further clinical studies.
|
